Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02417701 · ClinicalTrials.gov registry record · Phase 2
Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02417701: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02417701 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02417701, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This phase II trial studies how well sapanisertib works in treating patients with lung cancer that is stage IV or has come back (recurrent) and has a mutation in the NFE2L2, KEAP-1, or KRAS gene. Damage to these genes may cause the cancer to grow. Sapanisertib may stop this from happening by blocking enzymes.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Sapanisertib
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-10-06 |
| Est. Completion | 2020-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02417701
The ClinicalTrials.gov registry entry for NCT02417701 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02417701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02417701 about?
NCT02417701 is a clinical study titled "Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer". This phase II trial studies how well sapanisertib works in treating patients with lung cancer that is stage IV or has come back (recurrent) and has a mutation in the NFE2L2, KEAP-1, or KRAS gene. Damage to these genes may cause the cancer to grow. Sapanisertib may stop this from happening by blockin...
What is the current status of trial NCT02417701?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2016-10-06. Estimated completion is 2020-12-28.
What interventions are being tested in trial NCT02417701?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Sapanisertib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02417701?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.